Pembrolizumab with chemotherapy for HR+/HER2- locally recurrent inoperable or metastatic breast cancer

Pembrolizumab in combination with chemotherapy is currently in clinical development for metastatic or locally recurrent, inoperable breast cancer. Symptoms of breast cancer can include a lump or a thickened area of breast tissue, changes in the size of the breasts, discharge from the nipples, and lumps or swelling underneath the armpits. When breast cancer becomes metastatic, this means it has spread to other parts of the body. If a cancer is locally recurrent, it means that it has come back into the breast, armpit, or chest wall after already being treated. Currently, breast cancer is the second most common form of cancer death among women but there are few recommended treatments for people with metastatic or locally advanced, inoperable breast cancer.